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Abstract objectives HIV infection is associated with chronic systemic inflammation, with or without
antiretroviral therapy. Consequences for foetal growth are not understood, particularly in settings
where multiple maternal infections and malnutrition are common. The study was designed to
examine maternal systemic circulating and umbilical cord blood cytokine concentrations in relation
to birth anthropometry in a Tanzanian prospective cohort.
methods A 9-plex panel of maternal plasma cytokines in HIV-positive (n = 44) andHIV-negative
(n = 70) mothers and the same cytokines in umbilical cord blood collected at delivery was assayed. Linear
regression modelled associations between maternal or cord blood cytokines and birth anthropometry.
results Health indicators (haemoglobin, mid-upper-arm circumference, body mass index) in HIV-
positive mothers without considerable immunosuppression did not differ from HIV-negative women.
Despite this, HIV-exposed infants had lower birthweight and length. Subgroup analyses indicated that
HIV management using HAART was associated with lower plasma TNF-a, as were longer durations
of any antiretroviral therapy (≥2 months). Greater maternal plasma TNF-a was associated with
earlier delivery (1.7 weeks, P = 0.039) and lower birthweights (287 g; P = 0.020), while greater
umbilical cord TNF-a (1.43 cm; P = 0.036) and IL-12p70 (2.4 cm; P = 0.008) were associated
with shorter birth length. Birthweight was inversely associated with cord IL-12p70 (723 g;
P = 0.001) and IFN-c (482 g, P = 0.007). Maternal cytokines during pregnancy did not correlate
with umbilical cord cytokines at delivery.
conclusions Systemic inflammation identified in maternal plasma or umbilical cord blood was
associated with poorer birth anthropometrics in HIV-exposed and HIV-unexposed infants.
Controlling maternal and/or foetal systemic inflammation may improve birth anthropometry.
keywords Africa, birthweight, foetal, pregnancy, rural health, tumour necrosis factor-alpha
Introduction
Dysregulation of immune processes and persistent inflam-
mation is present at all stages of HIV infection, with
incomplete normalisation of inflammatory cytokines even
after highly active antiretroviral therapy (HAART)-asso-
ciated viral suppression and immunological stability is
achieved [1–3]. Inflammation has widespread detrimental
effects on immune function and overall health [4, 5], and
maternal inflammation is associated with adverse birth
outcomes [6–11] including intrauterine growth restriction
(IUGR) and preterm birth, a leading global cause of
neonatal morbidity and mortality. Interpretation of
inflammatory-associated obstetrical and neonatal
consequences in the context of HIV infection is difficult
as data remain scarce. Furthermore, investigation of these
relationships is needed in a global health context given
the additional contributors to maternal inflammation
common in low-resource countries where frequent patho-
gen exposure and associated immune activation, malnu-
trition and insufficient medical care are common
[12, 13].
Systemic maternal inflammation may also impact foetal
growth indirectly mediated via maternal malnutrition
pathways. Elevated pro-inflammatory cytokines are
known to disrupt central and peripheral regulation of
appetite, weight and body composition [14]. While severe
manifestations may be unlikely in healthy pregnant
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women, low-grade systemic maternal inflammation may
sufficiently disturb maternal appetite and weight-regula-
tory mechanisms and have unknown spill-over conse-
quences on foetal growth and development. Importantly,
these consequences may remain masked by pregnancy
changes. Understanding all mechanisms linking maternal
malnutrition and foetal growth impairment is necessary
as the best interventions to resolve maternal malnutrition
due to inflammation-associated processes or due to pov-
erty-associated food insecurity will be different.
The main objective of this study was to investigate
relationships between systemic circulating cytokine con-
centrations in maternal plasma and umbilical cord blood
with foetal growth estimated by birth anthropometry.
Prioritised selection of cytokines was made according to
documented roles in pro-inflammatory, anti-inflammatory
and/or appetite, body weight/composition regulatory pro-
cesses. We hypothesised that systemic maternal or foetal
inflammation would correspond to poorer birth anthro-
pometry and that HIV-positive pregnant women would
have greater systemic inflammation than HIV-negative
pregnant women.
Methods
Study population
This prospective cohort study was conducted in Kisesa
ward, a rural and semirural region of Magu District in
north-western Tanzania. Participants were recruited from
the semirural antenatal clinic based at the Tanzanian gov-
ernment-run Kisesa Health Centre and from regional rurally
based primary healthcare dispensaries. Eligible women had
confirmed HIV serostatus (screening with DetermineTM
HIV-1/2 [Inverness Medical] and confirmation with Uni-
GoldTM HIV-1/2 [Trinity Biotech]), a stated intention to
remain in the cohort catchment area for the duration of
pregnancy and delivery, and singleton births. High-risk
pregnancies were excluded as these mothers were offered
care at the district hospital in Mwanza City. HIV-positive
women were receiving ART by delivery, but routine viral
load analyses were unavailable at this semirural clinic. All
women were encouraged to deliver at Kisesa Health Centre,
with compensation for clinic and transportation costs pro-
vided by the study. Recruitment occurred between March
and November 2012, with follow-up interviews continuing
until all participants had delivered.
Ethical statement
All participants provided written informed consent for
themselves and on behalf of their infants. Ethical
approval was granted by the Tanzanian National Health
Research Ethics Review Committee, Cornell University,
and the University of Virginia Institutional Review
Boards.
Data collection
Maternal and infant demographic, obstetrical and health
questionnaires were administered in Kiswahili by the
study nurse, with anthropometrics obtained by trained
research nurses. Gestational age was estimated based on
date of last menstrual period (LMP), or fundal height if
LMP was unknown. As part of the Tanzanian standard
of antenatal care, maternal haemoglobin concentration
was determined using a Hemo-Control photometer (EKF
Diagnostics, Magdeburg, Germany). Maternal weight
was measured to the nearest 0.2 kg and height to the
nearest 0.1 cm, using a mechanical beam scale with
height rod (Health O Meter, Inc., Bridgeview, IL). Mater-
nal mid-upper arm circumference (MUAC) was obtained
using a tape measure to the nearest 0.1 cm. Birth anthro-
pometry (weight, length, MUAC, head circumference)
was obtained within a maximum of 72 h of delivery.
Infant weight was measured to the nearest 0.01 kg using
a digital infant scale (Seca 334 Digital Baby Scale), length
to the nearest 0.1 cm using a length board and MUAC
and head circumference to the nearest 0.1 cm using a
tape measure. Scales were calibrated weekly according to
manufacturer instructions. Data regarding pregnancy out-
comes (live birth, stillbirth, miscarriage) were obtained
from participant self-report or clinic records.
Laboratory methods
Maternal blood was collected at enrolment, and venous
umbilical cord blood (UCB) was collected immediately
after delivery from the subset of mothers that choose to
deliver at Kisesa Health Centre. BDTM P800 Blood Col-
lection System tubes (cat# 366421) containing DPP-IV,
esterase and other protease inhibitors were used for blood
collection. Up to 5 ml of whole blood was collected in
each tube, and blood samples were centrifuged at 1000 g
for at least 10 min to isolate plasma. Plasma was ali-
quoted into microcentrifuge tubes and stored at 20 °C
until batch analysis within 1 year of collection. Cytokines
[tumour necrosis factor (TNF)-a, interferon (IFN)-c,
interleukin [IL]-10, IL-12p70, IL-15, IL-13, IL-1b, IL-2,
IL-6] in maternal peripheral blood and from UCB were
measured using MAGPIX instrumentation with xMAP
technology (Luminex Corporation, TX) and MILLI-
PLEX MAG magnetic bead-based multi-analyte panels
(EMD Millipore, MA; cat# HCYTOMAG-60K). All
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procedures were performed in accordance with the manu-
facturer’s instructions including manufacturer-provided
quality controls as well as laboratory-specific pooled
plasma quality assurance samples as internal controls. A
plate passed quality checks if the mean plate coefficient
of variation was <10%. If analyte concentrations were
below the assay limit of detection (LOD; 3.2 pg/ml for
all cytokines), the test sample was repeated.
Statistical analysis
All data were analysed using STATA12 (STATA Corpo-
ration, Texas, USA) with a statistical significance level set
at a = 0.05 with two-sided hypothesis testing.
TNF-a was selected as the primary analyte for sample
size calculations given the availability of literature in the
context of HIV infection, and cytokine-associated appe-
tite and body weight-regulatory mechanisms described in
other clinical conditions. Accordingly, a sample size of
41 per comparison group was calculated based on a
mean concentration difference in serum TNF-a of 20 pg/
ml between HIV-positive and HIV-negative mothers
extrapolated from data in a USA-based cohort [15],
assuming a standard deviation (SD) of 32 pg/ml, a power
of 80% and a two-sided significance level of 5%. For
every HIV-positive woman enrolled, 1–2 HIV-negative
women were recruited to serve as a comparison. Addi-
tional participants were recruited as study exits prior to
delivery were expected due to miscarriage, stillbirth, non-
singleton pregnancies or study withdrawals.
To investigate relationships between maternal HIV-
related health indicators or HIV management differences
with maternal cytokine concentrations, a subgroup analy-
sis was conducted where HIV-positive women were clas-
sified according to (i) CD4 cell count [≥350 vs. <350
cells/ll, representing the CD4 threshold for antiretroviral
therapy (ART) eligibility in Tanzania at the time of data
collection]; (ii) ART duration (not taking ART or ART
duration <2 months vs. ART duration ≥2 months); and
(iii) ART regimen (none, AZT only vs. HAART).
Undetectable cytokine concentrations are common in
multiplex analyses, and concentration differences (HIV-
positive vs. HIV-negative women; HIV-exposed vs. HIV-
unexposed infants) were analysed according to the pro-
portion of detectable samples in the assay. For those ana-
lytes where ≥20% of all samples had concentrations
≥LOD, values were natural log-transformed and analysed
using Student’s t-test. These data were back-transformed
with geometric means and confidence intervals reported.
The proportion of samples detectable (≥LOD) vs. unde-
tectable (<LOD) was compared using the Pearson chi-
square test.
Relationships between birth anthropometric measure-
ments and maternal plasma or UCB cytokines were inves-
tigated using linear regression adjusted for infant sex;
maternal plasma models were also adjusted for gesta-
tional age at blood collection. In the absence of defined
clinically relevant cut-offs, if <20% of samples equalled
or were >LOD, values were simply classified as either
‘Higher’ (≥LOD) or ‘Lower’ (<LOD). For analytes with
≥20% of samples equal or >LOD, analytes were dichoto-
mised based on the quartile distribution of the observed
data into ‘Higher’ (highest quartile) or ‘Lower’ (lowest
three quartiles combined).
Biological effects of cytokine networks are likely, and
to explore the association between multiple UCB cytoki-
nes and birthweight, a novel scoring index was devel-
oped. Individual UCB cytokine scores were obtained by
summing the number of ‘Higher’ cytokine classifications
across each participant. These participant summary UCB
cytokine scores were then classified into mutually exclu-
sive categories defined as Low = 0 ‘Higher’ classifications
across all cytokines for that participant; Moderate = 1–3
‘Higher’ cytokine classifications for that participant; High
≥4 ‘Higher’ classifications for the participant.
Results
Cohort follow-up
The majority of women (n = 114) were followed through
delivery (88%, 100/114; all deliveries were vaginal).
Study exits prior to delivery included miscarriage (3%,
n = 3/114, all HIV positive), stillbirth (2%, n = 2/114,
both HIV negative), moved (5%, n = 6/114; 3 HIV posi-
tive, 3 HIV negative) or unspecified reasons (3%, n = 3/
114; all HIV negative). Of the 100 infants delivered in
the cohort, birthweight was available for 91% (92%,
n = 35/38 HIV positive; 90%, n = 56/62 HIV negative)
and complete birth anthropometry from 79% (79%,
n = 30/38 HIV positive; 79%, n = 49/62 HIV negative).
UCB samples were obtained from the entire subset of
women who chose to deliver at the clinic (50%, 19/38
HIV positive; 50%, n = 31/62 HIV negative). All HIV-
exposed infants in the cohort at 3 months of age were
HIV seronegative.
Maternal and infant characteristics
Characteristics of women and their newborns are sum-
marised in Table 1. Cohort enrolment was at a mean ges-
tational age of 26.9 weeks (SD = 6.9). Generally, women
were not severely undernourished according to body mass
index (BMI) and MUAC as mean BMI was 23.4 kg/m2
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(SD  2.6) compared to a commonly used pregnancy
underweight cut-off of ≤20 kg/m2 [16], and only three
women had MUAC <22 cm, a pregnancy wasting cut-off
previously reported [17]. No women met the definition
for adult stunting (height <145 cm). Women did not self-
report antibiotic, cotrimoxazole or tuberculosis therapy
during the study, and few HIV-positive women were
experiencing severe immunosuppression given 45% had
normal CD4 cell counts (defined as >500 cells/ll). The
majority of women were anaemic (55% n = 49/89;
according to haemoglobin <11 g/dl) with no differences
based on HIV seropositivity (mean  SD: haemoglobin
concentration HIV positive=10.7  1.8 vs. HIV nega-
tive = 10.4  1.7 g/dl; P = 0.532).
Obstetrical self-reported history indicated that approxi-
mately one of five women had experienced a previous
miscarriage and one of ten a previous stillbirth, with a
clinically relevant but not statistically significant greater
frequency among HIV-positive women (vs. HIV-negative
women: miscarriage 27 vs. 16%, P = 0.134; stillbirth 18
vs. 7%, P = 0.071). While 30% of deliveries were pre-
term (defined as delivery <37 weeks gestation), only 5%
of newborns were low birthweight (LBW; defined as
<2500 g) and only 7% were small-for-gestational age
Table 1 Cohort characteristics of HIV-positive and HIV-negative pregnant women and their HIV-exposed and HIV-unexposed infants
HIV-positive mothers HIV-negative mothers
P*n Mean  SD, median (IQR) or % n Mean  SD or %
Maternal characteristics
Age (years) 44 28.9  6.0 70 27.4  6.0 0.192
Parity 44 2.5  1.9 70 2.4  1.7 0.780
Body mass index (kg/m2) 44 23.4  2.9 70 23.4  2.5 0.928
Mid-upper arm circumference (cm) 44 27.3  2.9 70 26.6  2.5 0.192
CD4 cell count (cells/ll) 43 459 (330-774)
≥500 20 46.5
350–499 12 27.9
200–349 7 16.3
<200 4 9.3
Antiretroviral regimen at enrolment
AZT only for PMTCT 24 54.5
HAART 15 34.1
None 5 11.4
HIV-exposed infants HIV-unexposed infants
P*n Mean  SD or % n Mean  SD or %
Pregnancy outcomes
Foetal or neonatal death† 3 7.3 2 3.1 0.325
Gestational age at delivery (weeks) 38 37.7  3.0 62 38.4  3.6 0.274
Preterm delivery (<37 weeks) 13 34.2 17 27.4 0.472
Birthweight (g)‡ 35 3010  515 56 3265  403 0.010
Low birthweight (<2500 g) 3 8.6 2 3.6 0.309
Birth length (cm)§ 30 45.8  0.5 49 47.0  0.2 0.012
Birth head circumference (cm)§ 30 34.1  0.3 49 34.2  0.5 0.854
Birth mid-upper arm circumference (cm)§ 30 10.5  0.2 49 11.3  0.5 0.245
AZT, zidovudine; HAART, highly active antiretroviral therapy; IQR, interquartile range; PMTCT, prevention of mother-to-child trans-
mission of HIV; SD, standard deviation.
*P-value is for comparisons made between HIV-positive vs. HIV-negative mothers or HIV-exposed vs. HIV-unexposed infant groups.
Student’s t-test was used for continuous variables and Pearson chi-square test for categorical variables.
†Foetal or neonatal death was defined as self-reported miscarriage or stillbirth.
‡Infant birthweight was available <72 h from delivery from n = 91/100 of cohort at delivery (HIV positive: 35/38 [92%]; HIV nega-
tive: 56/62 [90%]).
§Detailed birth anthropometry was available <72 h from delivery from n = 79/100 participants (HIV positive: 30/38 [79%]; HIV nega-
tive: 49/62 [79%]).
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(defined as birthweight <10th percentile for gestational
age). Despite similar maternal health characteristics
between HIV-positive and HIV-negative women including
BMI, anaemia and limited evidence of severe immunosup-
pression as approximately three-fourth of HIV-positive
women had absolute CD4 cell counts >350 cell/ll, in
utero HIV exposure was still associated with a 255 g
lower birthweight (P = 0.010) and a 1.2 cm shorter birth
length (P = 0.012).
Maternal systemic inflammation and birth outcomes
Circulating cytokine concentrations in maternal plasma
are summarised in Table 2. TNF-a was the most fre-
quently detected cytokine in maternal plasma samples
(96%), with IFN-c, IL-12p70, IL-15 and IL-10 detectable
in >20% of participants. TNF-a (100 vs. 93%,
P = 0.045) and IL-15 (35 vs. 20%, P = 0.002) were more
frequently detected in the last trimester compared to the
second, with no differences observed for other cyto-
kines. Examination of the maternal cytokine correlation
matrix indicated a complex pattern of associations.
Maternal plasma TNF-a was correlated with the anti-
inflammatory cytokine, IL-10 (Pearson correlation coeffi-
cient r = 0.42, P < 0.001); IL-10 with IL-12p70
(r = 0.42, P = 0.029) and IL-15 (r = 0.45, P = 0.038);
IL-15 with IL-12p70 (r = 0.57, P = 0.013) and IFN-c
(r = 0.48, P = 0.025).
Maternal systemic inflammation indicated by higher
plasma TNF-a concentrations was associated with HIV
Table 2 Maternal plasma and umbilical cord blood cytokine concentrations, according to maternal HIV seropositivity or infant HIV
exposure
Maternal plasma
cytokines (pg/ml)
HIV positive (n = 44/44) HIV negative (n = 70/70)
P† P‡
Detectable %
(n/total assayed)
Geometric
mean* 95% CI
Detectable %
(n/total assayed)
Geometric
mean* 95% CI
TNF-a 93.2 (41/44) 70.8 (64.5, 77.7) 98.6 (69/70) 62.0 (58.3, 65.9) 0.128 0.014
IFN-c 38.6 (17/44) 44.6 (34.4, 57.7) 54.3 (38/70) 53.4 (44.8, 63.6) 0.104 0.242
IL-12p70 18.2 (8/44) 59.1 (34.3, 101.9) 32.9 (23/70) 59.4 (49.6, 71.0) 0.086 0.983
IL-15 11.4 (5/44) 34.5 (28.3, 42.1) 28.6 (20/70) 41.9 (33.7, 52.1) 0.031 0.376
IL-10 75.0 (33/44) 58.4 (47.5, 71.8) 81.4 (57/70) 59.2 (51.1, 68.6) 0.412 0.910
IL-1b 0.0 (0/44) 4.3 (3/70) 0.164
IL-6 4.6 (2/44) 4.3 (3/70) 0.947
IL-2 2.3 (1/44) 2.9 (2/70) 0.849
IL-13 0.0 (0/44) 4.3 (3/70) 0.164
Umbilical cord
blood cytokines (pg/ml)
HIV exposed (n = 19/38) HIV unexposed (n = 31/62)
P† P‡
Detectable %
(n/total assayed)
Geometric
mean* 95% CI
Detectable %
(n/total assayed)
Geometric
mean* 95% CI
TNF-a 100.0 (19/19) 84.7 (72.7, 98.7) 100.0 (31/31) 86.4 (74.1, 100.9) NA 0.859
IFN-c 36.8 (7/19) 41.0 (12.7, 131.7) 16.1 (5/31) 92.0 (12.7, 131.7) 0.096 0.104
IL-12p70 47.4 (9/19) 60.2 (36.4, 99.6) 64.5 (20/31) 69.0 (49.3, 96.6) 0.233 0.315
IL-15 52.6 (10/19) 232.6 (64.9, 833.2) 36.7 (11/31) 125.6 (40.5, 389.4) 0.271 0.787
IL-10 21.1 (4/19) 16.1 (5/31) 0.660
IL-1b 15.8 (3/19) 9.7 (3/31) 0.519
IL-6 15.8 (3/19) 12.9 (4/31) 0.775
IL-2 0.0 (0/19) 0.0 (0/31)
IL-13 5.3 (1/19) 0.0 (0/31)
IFN, interferon; IL, interleukin; NA, not applicable as both were 100% detectable; TNF, tumour necrosis factor.
*For cytokines in which ≥20% of all samples (HIV positive and HIV negative combined) had detectable (≥LOD) analyte concentra-
tions, absolute concentrations were natural log-transformed for statistical testing, and back-transformed with geometric means and con-
fidence intervals reported.
†P-value was obtained using the Pearson chi-square test comparing the proportion of samples with detectable (≥LOD) analyte concen-
trations between HIV-positive vs. HIV-negative or HIV-exposed vs HIV-unexposed groups.
‡P-value obtained using Student’s t-test comparing mean natural log-transformed concentrations of detectable (≥LOD) analyte concen-
trations between HIV-positive vs. HIV-negative or HIV-exposed vs HIV-unexposed groups.
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seropositivity, greater immunosuppression, non-HAART
regimens and shorter duration (<2 months) of any ART
regimen (Figure 1). Corresponding patterns were
observed for IL-10, although associations were not
statistically significant except for higher IL-10 among
HIV-positive women receiving ART for <2 months. Sub-
group analyses were not conducted for remaining cytoki-
nes due to small numbers with detectable concentrations.
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Figure 1 Association between maternal circulating plasma TNF-a (a–b) or IL-10 (c–d) concentration and immunosuppression or HIV
treatment. Rectangles represent predicted marginal means, and bars represent the upper 95% confidence interval limit obtained from
linear regression analyses, adjusting for gestational age at blood collection. Data were natural log-transformed for statistical testing.
TNF-a/IL-10 group sizes: HIV negative = 69/57; CD4 <350 = 11/6; CD4 ≥350 = 29/26; antiretroviral therapy (ART) <2 months = 23/
20; ART ≥2 months = 18/13; no ART = 5/4; AZT only = 23/19; HAART = 13/10.
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In adjusted linear regression analyses of birth anthro-
pometry or gestational age (Table 3), systemic inflamma-
tion according to maternal circulating plasma TNF-a was
associated with poorer birth outcomes. Specifically,
greater TNF-a concentration in maternal plasma was
associated with both gestational age at delivery and birth-
weight. Greater maternal plasma TNF-a was also associ-
ated with lower gestational age-adjusted birthweight
(b = 254 g, P = 0.032), suggesting the relationship
between greater maternal inflammation and lower birth-
weight is not fully explained by duration of gestation.
Other maternal plasma cytokines were not associated
with birth outcomes (Table 3), nor were they associated
with foetal loss, preterm delivery or LBW (data not
shown).
Umbilical cord blood inflammation and birth outcomes
Umbilical cord blood cytokines are summarised in
Table 2. Among analytes with ≥20% of values at or
exceeding the LOD (TNF-a, IFN-c, IL-12p70, IL-15),
none were significantly correlated with each other. IL-2
was undetectable in all samples, and IL-13 was detectable
in a single sample. In this cohort, neither the proportion
of detectable UCB cytokines nor the absolute concentra-
tions varied according to foetal HIV exposure. Associa-
tions between maternal plasma cytokines collected during
the second or third trimester and UCB cytokines at deliv-
ery were not statistically significant (data not included).
Greater UCB inflammation was associated with lower
birthweight or shorter length, but not with gestational
Table 3 Maternal plasma and foetal umbilical cord cytokines and association with birth outcomes
Gestational age at
delivery (weeks)
Birthweight (g)
(n = 91) Birth length (cm)
Birth head
circumference (cm)
b SE P b SE P b SE P b SE P
Maternal plasma cytokines* (n = 100) (n = 91) (n = 79) (n = 79)
TNF-a* 1.69 0.81 0.039 287 121 0.020 0.01 0.62 0.991 0.63 0.94 0.505
IL-1b‡ 1.73 2.00 0.389 43 283 0.881 0.98 1.26 0.440 0.23 1.92 0.903
IL-6‡ 0.09 1.72 0.958 197 276 0.478 1.07 1.51 0.480 0.40 2.30 0.863
IFN-c* 0.31 0.80 0.698 44 117 0.707 0.11 0.54 0.837 0.12 0.82 0.888
IL-2‡ 2.47 2.37 0.301 316 334 0.346 1.35 1.49 0.367 0.91 2.27 0.688
IL-12p70* 0.03 0.80 0.971 58 119 0.627 0.83 0.55 0.139 0.13 0.85 0.883
IL-15* 0.42 0.82 0.607 43 120 0.720 0.21 0.57 0.721 0.05 0.87 0.953
IL-10* 1.28 0.87 0.143 7 128 0.959 0.74 0.62 0.237 0.71 0.94 0.452
IL-13‡ 3.79 2.35 0.111 239 335 0.477 0.83 1.49 0.578 0.38 2.27 0.868
Umbilical cord blood cytokines§ (n = 50) (n = 50) (n = 50) (n = 50)
TNF-a* 1.70 1.09 0.128 273 159 0.093 1.43 0.66 0.036 3.21 1.10 0.010
IL-1b‡ 0.63 1.36 0.648 374 192 0.058 1.40 0.82 0.094 0.22 1.55 0.890
IL-6‡ 2.10 1.08 0.057 241 162 0.144 0.70 0.70 0.319 0.68 1.28 0.600
IFN-c* 0.60 1.25 0.635 482 170 0.007 1.13 0.76 0.143 0.18 1.43 0.902
IL-2‡ ND
IL-12p70* 1.71 1.50 0.259 723 196 0.001 2.40 0.87 0.008 0.07 1.72 0.968
IL-15* 1.18 1.11 0.292 271 159 0.095 0.72 0.68 0.298 0.51 1.27 0.692
IL-10‡ 0.84 1.10 0.452 189 160 0.245 0.09 0.69 0.898 0.52 1.26 0.680
IL-13‡ ND
IL, interleukin; IFN, interferon; ND, undetectable in any IL-2 and only in a single IL-13 sample; SE, standard error; TNF, tumour
necrosis factor.
Bold font indicates association statistically significant at P < 0.05.
*Linear regression models with maternal plasma were adjusted for gestational age at blood draw and for infant sex.
†Analytes in which ≥20% of all samples (HIV positive and HIV negative combined) had detectable (≥LOD) concentrations, cytokine
concentrations were dichotomised based on the distribution of the observed data into ‘Higher’ (highest quartile; coded 1) or ‘Lower’
(lowest three quartiles combined, coded 0).
‡Analytes in which <20% of all samples (HIV positive and HIV negative combined) had detectable (≥LOD) concentrations, samples
were coded as ‘Higher’= detectable defined as ≥LOD or ‘Lower’ = undetectable or <LOD.
§Linear regression models with umbilical cord blood were adjusted for infant sex.
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age at parturition (Table 3). Infants with greater UCB
IFN-c and IL-12p70 had significantly lower birthweights.
Higher IL-12p70 was also associated with shorter birth
length, while higher TNF-a was associated with lower
birth length and smaller head circumferences. In models
adjusted for infant sex using absolute concentrations of
natural log-transformed cytokines, IFN-c and IL-12p70
were associated with lower birthweight (b = 135,
P = 0.004; b = 176, P = 0.001, respectively) and IL-
12p70 was also associated with shorter birth length
(b = 0.55; P = 0.012). There were no significant associ-
ations between birth MUAC and UCB cytokines (data
not shown).
Using the UCB cytokine index, the combined exposure
to multiple UCB cytokines at higher concentrations was
related to poorer birth outcomes (Figure 2). The highest
UCB cytokine score category was associated with a 550 g
lower birthweight compared to the lowest UCB cytokine
score category (P = 0.004), and a 664 g lower birth-
weight compared to the moderate UCB cytokine score
category (P = 0.001). There were no significant associa-
tions between UCB cytokine scores and birth length,
MUAC or head circumference.
Discussion
In this prospective cohort, pregnant HIV-positive women
experienced greater inflammation compared to HIV-nega-
tive pregnant women living in rural and semirural Tanza-
nia. This study provides evidence that suboptimal HIV
management (non-HAART regimens) or a shorter dura-
tion of ART is associated with elevated inflammation
among pregnant women with HIV infection. From a clin-
ical perspective, this observation lends further support to
the September 2015 WHO recommendation to include
pregnant women in the ‘treat all’ at HIV diagnosis with
HAART [18]. In a resource-restricted sub-Saharan Afri-
can setting, many women experience self-limiting or
chronic subclinical infections, and this study provides evi-
dence that poorer birth anthropometry is associated with
maternal or cord blood systemic inflammation, irrespec-
tive of maternal HIV status or the cause of inflammation.
Consequently, interventions aimed at improving birth
anthropometry in this setting should also consider that
systemic inflammation may be driving foetal growth
impairment, and in this context, nutritional interventions
alone would likely be insufficient to improve foetal
growth outcomes. Normal pregnancy is a state of care-
fully controlled immune modulation that is yet to be fully
understood. The first trimester is characterised by a mild
inflammatory state, followed by a subtle shift towards T
helper 2-type cytokines as pregnancy progresses [19, 20].
Overall, cytokines play important roles in maintaining a
healthy pregnancy, and disturbances in maternal cytokine
profiles have been linked to adverse pregnancy outcomes
[8, 21–24]. This study found that although HIV infection
is associated with greater maternal inflammation, sys-
temic maternal or UCB inflammation was associated with
less favourable birth outcomes and intrauterine growth
among both HIV-exposed and HIV-unexposed infants.
Predicted birthweight, 95% CI
Low
birthweight
2000 2500 3000 3500 4000
Low UCB cytokine index
(n = 23)
Moderate UCB cytokine index
(n = 19)
High UCB cytokine index
(n = 8)
Grams
Figure 2 Relationship between umbilical cord blood cytokine (UCB) index and birthweight. Points represent predicted marginal
means, and bars represent 95% confidence intervals obtained from linear regression analysis of the main outcome birthweight, adjusted
for infant sex. The UCB index was determined based on the number of cytokine concentrations classified as “Higher” in UCB and then
summed for each infant. The summary UCB index was classified as Low = no cytokine concentrations were “Higher”; Moderate = 1–3
cytokines were “Higher”; High ≥4 cytokines were “Higher”.
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Further investigation of potential subgroup differences,
temporal relationships and a better mechanistic under-
standing of the foetal consequences associated with
greater maternal and/or UCB TNF-a, IFN-c, IL-12p70
and IL-10 cytokines is needed. Furthermore, although it
is important to understand single cytokine effects, this
study provides preliminary evidence using a cytokine
score that the combined consequences of multiple cytoki-
nes are important to consider in future studies.
Although maternal HIV care with HAART regimen
and longer duration was associated with TNF-a concen-
trations similar to HIV-negative women, the overall mean
TNF-a concentrations in both HIV-positive and HIV-
negative women in this cohort were higher than a US-
based cohort of HIV-positive pregnant women (70.8 vs.
20.6 pg/ml) [15]. The higher maternal plasma TNF-a
concentration among study participants suggests that
chronic pathogen exposure and associated immune acti-
vation from non-HIV infectious diseases or other inflam-
matory stimuli associated with living in a rural and
semirural developing country setting may have broad
implications for foetal growth in all pregnancies. Under-
standing mediators of foetal growth is important as a
poorer start to life may have ongoing health implications
[25]. Furthermore, exposure to a nutritionally or
immunologically imbalanced intrauterine environment
may result in epigenetic adaptations that increase disease
risk later in life [26].
In the current study, higher maternal plasma TNF-a
was associated with smaller birthweights, even after
adjustment for gestational age at delivery. Previous stud-
ies examining associations between foetal growth restric-
tion and peripheral circulating maternal pro-
inflammatory and anti-inflammatory cytokines have pro-
duced heterogeneous results. This may be related to the
complexity in interpreting dynamic cytokine profiles, dif-
ferences in assay methodologies or coexisting pathologies
causing foetal growth restriction [7, 8, 27–29]. In a Span-
ish cohort of HIV-negative women, Bartha et al. [28]
reported that elevated maternal TNF-a was associated
with foetal growth restriction, with similar results for
small-for-gestational age outcomes observed in an HIV-
seronegative Dutch cohort [27]. Together, these studies
provide additional support that pro-inflammatory cytoki-
nes are associated with restricted foetal growth, although
the mechanisms remain unidentified. TNF-a may con-
tribute to pregnancy complications through several differ-
ent pathways and is believed to mediate preterm labour
by stimulating prostaglandin production and activating
matrix metalloproteinases [30].
Estimating the intrauterine cytokine environment repre-
sents a distinct and proximal foetal exposure. In this
study, greater TNF-a, IL-12p70 and IFN-c in UCB corre-
sponded to poorer birth anthropometry, and although
UCB and foetal growth studies are very limited, a US
study observed that greater UCB IFN-c or IL-12p70 was
associated with protection against small-for-gestational
age, particularly among HIV-unexposed infants born pre-
term [31]. Authors speculated that the unexpected direc-
tion of associations was possibly due to reverse causality
whereby healthier foetuses mounted more robust immune
responses. Cytokine differences were evident in a South
African cohort that reported HIV-exposed infants had
increased UCB PHA-stimulated IL-10 and a trend
towards greater PHA-stimulated IFN-c concentrations
compared to HIV-unexposed infants [32], while UCB
IFN-c was lower in Danish HIV-exposed infants com-
pared to HIV-unexposed infants [33]. Discrepancies in
cytokine results may be related to cohort differences in
rates of elective caesarean section, health characteristics
of HIV-positive participants and other factors. It may
also be important to consider non-urban populations in
sub-Saharan Africa as distinct given the many unique
health and healthcare accessibility differences that may
contribute to systemic inflammation. Although designed
to investigate the consequences of altered cytokine con-
centrations and inflammation, this study was not
designed to identify the causes. Enteric infection remains
a chronic problem, and malaria and syphilis are prevalent
in this setting and independently associated with inflam-
mation and negative birth outcomes. While none of the
participants in the current study were identified with
malaria or other sexually transmitted infections including
syphilis, subclinical infections cannot be ruled out as
maternal testing was conducted if symptoms were
reported or observed. An additional limitation was that
viral load was unavailable for these analyses.
Umbilical cord blood was used as a proxy for the foe-
tal environment because it provides an indication of the
recent, but not chronic, cytokine exposure that may be
biologically relevant for foetal growth. Use of maternal
plasma as a proxy for the longer-term foetal environment
does not appear justified given the lack of correlation in
this study. Others have also demonstrated that maternal
circulating pro-inflammatory cytokines are unlikely to
cross the placenta, except under conditions of stress and
increased foetal membrane permeability [34]. Simultane-
ously analysing multiple inflammatory, anti-inflammatory
and regulatory cytokines using multiplex methodology
has many advantages including time, sample volume and
resource savings compared to traditional ELISA tech-
niques; however, several cytokines had concentrations
<LOD. Although this was anticipated and consistent with
other studies [15, 35, 36], future studies should consider
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this during planning, especially if important subgroup dif-
ferences (e.g. comparisons among HIV-exposed infants,
comparisons including an HIV-negative non-pregnant
female group) are of interest.
In summary, this study demonstrates that systemic
maternal or umbilical cord blood inflammation is associ-
ated with poorer birth anthropometric measurements
among HIV-exposed and HIV-unexposed infants in this
setting. Maternal inflammation was greater in HIV-posi-
tive women, and improved maternal HIV care through
earlier HIV diagnosis and HAART initiation may confer
additional benefits by reducing inflammation and provid-
ing the best opportunity for foetal growth in HIV-exposed
infants. Future studies investigating the aetiological deter-
minants of gestational and foetal inflammation and mech-
anisms leading to suboptimal foetal growth are needed.
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